证券之星消息，12月29日中药板块较上一交易日下跌0.9%，*ST长药领跌。当日上证指数报收于 3965.28，上涨0.04%。深证成指报收于13537.1，下跌0.49%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002107 | 沃华医药 | 6.33 | 2.43% | 10.61万 | | 6558.20万 | | 600671 | 天目药业 | 17.39 | 1.81% | 2.26万 | | 3917.27万 | | 300878 | 维康药业 | 25.75 | 0.66% | 2.05万 | | 5303.78万 | | 600085 | 同仁堂 | 32.46 | 0.65% | 1 6.83万 | | 2.21亿 | | 002644 | 佛慈制药 | 8.82 | 0.23% | 12.26万 | | 1.07亿 | | 603139 | 康惠股份 | 20.38 | 0.20% | 1.22万 | | 2472.19万 | ...

从资金流向上来看，当日中药板块主力资金净流出3857.06万元，游资资金净流出9028.32万元，散户资 金净流入1.29亿元。中药板块个股资金流向见下表： 证券之星消息，12月19日中药板块较上一交易日上涨0.69%，维康药业领涨。当日上证指数报收于 3890.45，上涨0.36%。深证成指报收于13140.22，上涨0.66%。中药板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 ...

Core Viewpoint - The A-share market shows positive momentum with the Shanghai Composite Index closing at 3890.45 points, above the half-year line, reflecting a gain of 0.36% and a total trading volume of 1.748742 trillion yuan [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3890.45 points, above the half-year line, with a gain of 0.36% [1] - Total trading volume in the A-share market reached 1.748742 trillion yuan [1] Group 2: Stocks Breaking Half-Year Line - A total of 266 A-shares have surpassed the half-year line, indicating strong market interest [1] - Notable stocks with significant deviation rates include: - GQY Vision (10.23%) - Hongwei Technology (9.84%) - Zhongwang Fabric (8.75%) [1] Group 3: Detailed Stock Data - GQY Vision: Today's price increased by 11.23% with a turnover rate of 13.78%, latest price at 7.23 yuan [1] - Hongwei Technology: Today's price increased by 12.30% with a turnover rate of 17.12%, latest price at 27.49 yuan [1] - Zhongwang Fabric: Today's price increased by 9.98% with a turnover rate of 1.78%, latest price at 25.78 yuan [1]

Group 1 - The Shanghai Composite Index closed at 3887.81 points, above the six-month moving average, with a gain of 0.30% [1] - The total trading volume of A-shares reached 1,390.087 billion yuan [1] - A total of 249 A-shares have surpassed the six-month moving average, with notable stocks including GQY Vision, Hongwei Technology, and Zhongwang Fabric, showing significant deviation rates of 12.05%, 9.88%, and 8.75% respectively [1] Group 2 - GQY Vision (300076) had a daily increase of 13.08% with a turnover rate of 10.52%, and its latest price was 7.35 yuan, showing a deviation rate of 12.05% [1] - Hongwei Technology (688711) increased by 12.34% with a turnover rate of 15.68%, latest price at 27.50 yuan, and a deviation rate of 9.88% [1] - Zhongwang Fabric (605003) rose by 9.98% with a turnover rate of 1.76%, latest price at 25.78 yuan, and a deviation rate of 8.75% [1]

证券日报网讯 12月15日晚间，维康药业发布公告称，公司于近日取得浙江省药品监督管理局换发的 《药品生产许可证》，换发后的《药品生产许可证》有效期至2030年12月11日。 （文章来源：证券日报） ...

格隆汇12月15日丨维康药业(300878.SZ)公布，近日取得浙江省药品监督管理局换发的《药品生产许可 证》，换发后的《药品生产许可证》有效期至2030年12月11日。本次换发《药品生产许可证》是基于原 许可证即将到期，新证的取得确保了公司的正常生产经营，对公司业绩无重大影响。 ...

格隆汇12月15日丨维康药业（维权）(300878.SZ)公布，近日取得浙江省药品监督管理局换发的《药品 生产许可证》，换发后的《药品生产许可证》有效期至2030年12月11日。本次换发《药品生产许可证》 是基于原许可证即将到期，新证的取得确保了公司的正常生产经营，对公司业绩无重大影响。 ...

证券代码：300878 证券简称：维康药业 公告编号：2025-051 浙江维康药业股份有限公司 关于公司药品生产许可证变更的公告 质量负责人：纪晓燕 发证机关：浙江省药品监督管理局 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江维康药业股份有限公司（以下简称"公司"）于近日取得浙江省药品监 督管理局换发的《药品生产许可证》，换发后的《药品生产许可证》有效期至 2030 年 12 月 11 日，主要相关信息如下： 一、《药品生产许可证》基本情况 企业名称：浙江维康药业股份有限公司 注册地址：浙江省丽水经济开发区遂松路 2 号 社会信用代码：913311007047968289 法定代表人：刘洋 企业负责人：刘洋 有效期至：2030 年 12 月 11 日 许可证编码：浙 20000144 分类码：AhzyCh 生产地址和生产范围：浙江省丽水经济开发区遂松路 2 号：中药饮片〔含毒 性饮片、含直接口服饮片〕、丸剂（滴丸）、滴剂（胶囊型）（仅限注册申报使 用）、片剂、胶囊剂、软胶囊剂、颗粒剂*** 二、对公司的影响及风险提示 本次换发《药品生产许可证》是基于 ...

Investment Rating - The industry rating is maintained at "Overweight" [6] Core Insights - The Chinese medicine sector experienced a significant decline, with the Chinese medicine index dropping by 2.03% last week, while other pharmaceutical sub-sectors also faced declines, except for medical services which saw a 1.67% increase [1][19] - The price-to-earnings (PE) ratio for the Chinese medicine sector is 27.17X, down by 0.55X week-on-week, while the price-to-book (PB) ratio is 2.29X, down by 0.04X week-on-week [2] - The demand for flu-related and tonic herbs has increased, leading to a rise in the price index of Chinese medicinal materials, which is expected to continue to rise slightly in the future [3] - The national medical insurance work conference highlighted the restructuring of prices and market patterns as a major direction for the Chinese medicine industry in 2026, emphasizing the importance of collective procurement and support for innovation in the industry [4][9] Summary by Sections Market Performance - The Chinese medicine index closed at 6372.09 points, down 2.03% last week, with only the medical services sector recording positive returns [1][19] Valuation - The current PE ratio for the Chinese medicine sector is 27.17X, with a year-high of 30.26X and a year-low of 24.72X, placing it at the 28.41% percentile since 2013 [2] Supply Chain Insights - The price index for Chinese medicinal materials rose to 225.57 points, a 0.4% increase from the previous week, driven by increased demand due to the flu outbreak and winter tonic herbs [3] Policy and Market Trends - The 2026 direction for the Chinese medicine industry includes continued promotion of collective procurement and support for innovation, with an emphasis on price governance and market restructuring [4][10] - The focus on long-term care insurance is expected to increase demand for Chinese medicine products, particularly in the context of an aging population [9] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform, with specific recommendations for companies with strong R&D capabilities and unique products [10][11]

浙江维康药业股份有限公司 关于非独立董事辞职暨选举职工代表董事及补选董 事会专门委员会委员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：300878 证券简称：维康药业 公告编号：2025-050 三、关于补选董事会专门委员会委员情况 2025 年 12 月 10 日，公司召开第四届董事会第九次会议，审议通过了《关 于补选公司第四届董事会专门委员会委员的议案》，同意补选华杰女士为公司第 四届董事会战略决策委员会委员、提名委员会委员，任期自本次董事会审议通过 之日起至公司第四届董事会任期届满之日止。 四、备查文件 1、浙江维康药业股份有限公司第四届董事会第九次会议决议。 一、关于非独立董事辞职的情况 浙江维康药业股份有限公司（以下简称"公司"）董事会于近日收到公司非 独立董事兼副总经理孔晓霞女士的书面辞职报告。因公司治理结构调整，孔晓霞 女士申请辞去公司第四届董事会非独立董事职务，同时辞去董事会战略决策委员 会委员、提名委员会委员职务，原定任职日期至 2027 年 5 月 19 日。辞去上述职 务后仍担任公司副总经理职务。孔晓霞女士的辞职未导 ...